CO5780135A1 - Modulacion de los receptores activados por el proliferador de peroxisomas - Google Patents
Modulacion de los receptores activados por el proliferador de peroxisomasInfo
- Publication number
- CO5780135A1 CO5780135A1 CO06079383A CO06079383A CO5780135A1 CO 5780135 A1 CO5780135 A1 CO 5780135A1 CO 06079383 A CO06079383 A CO 06079383A CO 06079383 A CO06079383 A CO 06079383A CO 5780135 A1 CO5780135 A1 CO 5780135A1
- Authority
- CO
- Colombia
- Prior art keywords
- sec
- keto
- antibody
- isolated polypeptide
- peroxisom
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Physics & Mathematics (AREA)
- High Energy & Nuclear Physics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
Abstract
Un polipéptido aislado que comprende una secuencia según SEC. ID. NO: 1 o SEC. ID. NO: 3 o un equivalente funcional del mismo, donde el polipéptido reduce la 15-ceto prostaglandina. El polipéptido aislado de acuerdo con la reivindicación 1, que comprende una secuencia por lo menos 90 % idéntica a SEC. ID. NO: 1 o SEC. ID. NO: 3. El polipéptido aislado de acuerdo con la reivindicación 2, que comprende una secuencia por lo menos 80 % idéntica a SEC. ID. NO: 1 o SEC. ID. NO: 3. El polipéptido aislado de acuerdo con la reivindicación 1, en el cual el polipéptido es SEC. ID. NO: 1 o 3. El polipéptido aislado de acuerdo con la reivindicación 4, en el cual la 15-ceto prostaglandina es 15-ceto PGE2, 15-ceto PGE1, 15-ceto PGF2a, o 15-ceto PGF1a. El polipéptido aislado de acuerdo con la reivindicación 5, en el cual la 15-ceto prostaglandina es 15-ceto PGE2. Un anticuerpo donde el anticuerpo se une específicamente a un polipéptido de acuerdo con la reivindicación 1. Un anticuerpo de acuerdo con la reivindicación 7, donde el anticuerpo es un anticuerpo monoclonal. El anticuerpo de acuerdo con la reivindicación 7, donde el anticuerpo es SEC. IND. NO. 1.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70789705P | 2005-08-12 | 2005-08-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5780135A1 true CO5780135A1 (es) | 2007-07-31 |
Family
ID=37737230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO06079383A CO5780135A1 (es) | 2005-08-12 | 2006-08-11 | Modulacion de los receptores activados por el proliferador de peroxisomas |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070037193A1 (es) |
| EP (1) | EP1803809A3 (es) |
| JP (1) | JP2007061093A (es) |
| KR (1) | KR20080014936A (es) |
| CN (1) | CN1916167A (es) |
| AR (1) | AR054909A1 (es) |
| AU (1) | AU2006203479A1 (es) |
| BR (1) | BRPI0603206A (es) |
| CA (1) | CA2553115A1 (es) |
| CO (1) | CO5780135A1 (es) |
| IL (1) | IL177407A0 (es) |
| MX (1) | MXPA06009161A (es) |
| NO (1) | NO20063652L (es) |
| SG (1) | SG130141A1 (es) |
| TW (1) | TW200741003A (es) |
| ZA (1) | ZA200606661B (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2552108T3 (es) * | 2005-03-11 | 2015-11-25 | Howard Florey Institute Pty Ltd | Compuestos flavonoides y usos de los mismos |
| WO2009026657A1 (en) * | 2007-08-29 | 2009-03-05 | The University Of Sydney | Flavonoid ppar agonists |
| AU2009259543B2 (en) * | 2008-05-28 | 2015-09-03 | Basf Se | Means and methods for assessing increased peroxisomal proliferation |
| US20110306605A1 (en) * | 2008-12-22 | 2011-12-15 | Sloan-Kettering Institute For Cancer Research | Coumarin-based compounds for the treatment of alzheimer's disease and cancer |
| EP2389459B1 (en) * | 2009-01-21 | 2014-03-26 | George Atanasoff | Methods and systems for control of a surface modification process |
| EA015364B1 (ru) * | 2009-03-18 | 2011-06-30 | Учреждение Российской Академии Наук Институт Элементоорганических Соединений Им. А.Н. Несмеянова Ран (Инэос Ран) | 6,6'-диизопропил-8,8'-диметил-2,2'-динитро-3,3'-бис(трифторметил)- 3н,3'н-[9,9']ди[бензо(f)хроменил]-5,10,5',10'-тетраол, обладающий противоопухолевой и противогрибковой активностью, и способ его получения |
| CA2767616A1 (en) * | 2009-07-09 | 2011-01-13 | The Scripps Research Institute | Gene expression profiles associated with chronic allograft nephropathy |
| CN101948458B (zh) * | 2010-09-07 | 2012-11-07 | 中国药科大学 | 具有抗肿瘤活性的黄芩素衍生物及在医药上的应用 |
| CN102964322A (zh) * | 2012-12-12 | 2013-03-13 | 中国药科大学 | 异黄酮或类黄酮脂肪醚类衍生物、其制备方法和医药用途 |
| JP7029777B2 (ja) * | 2016-03-28 | 2022-03-04 | 国立大学法人金沢大学 | アンドロゲン依存性又は非依存性前立腺癌細胞の抑制用の組成物及びそれを含有する前立腺癌の医薬製剤 |
| CN107496414A (zh) * | 2017-09-21 | 2017-12-22 | 上海华堇生物技术有限责任公司 | 柽柳黄素的药物用途 |
| CN112645922B (zh) * | 2020-12-24 | 2022-01-07 | 中国人民解放军空军军医大学 | 香豆素类化合物、制备方法及应用 |
| CN115894422A (zh) * | 2022-12-26 | 2023-04-04 | 上海中医药大学 | PPARγ激动剂及其组合和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2543550B1 (fr) * | 1983-04-01 | 1985-08-09 | Cortial | Nouveaux derives de la tetrahydroxy-3', 4',5,7 flavone, leur methode de preparation et leur emploi therapeutique |
| US4587260A (en) * | 1984-06-21 | 1986-05-06 | Warner-Lambert Company | Dibenzalacetone and benzylcinnamate as non-steroidal anti-inflammatory compounds and compositions thereof |
| DE69130586T2 (de) * | 1990-05-01 | 1999-06-17 | R-Tech Ueno, Ltd., Osaka | Behandlung von Pankreaskrankheit mit 15-keto-Prostaglandin E-Derivaten |
| CA2046069C (en) * | 1990-07-10 | 2002-04-09 | Ryuji Ueno | Treatment of inflammatory diseases with 15-keto-prostaglandin compounds |
| ES2181923T3 (es) * | 1995-11-17 | 2003-03-01 | Upjohn Co | 4-hidroxicumarin-3-carboxamidas para el tratamiento de la diabet es mellitus no dependiente de la insulina. |
| AU5034200A (en) * | 1999-05-20 | 2000-12-12 | Incyte Genomics, Inc. | Oxidoreductase proteins |
| EP1267882B1 (en) * | 2000-03-24 | 2009-04-15 | Sucampo AG | Prostaglandins for the treatment of eye disease caused by light irradiation like photoretinitis |
| EP1402026A2 (en) * | 2000-04-18 | 2004-03-31 | Millennium Pharmaceuticals, Inc. | 39228, a human alcohol dehydrogenase and uses therefor |
| WO2001080855A1 (en) * | 2000-04-27 | 2001-11-01 | Geron Corporation | Telomerase inhibitors and methods of their use |
| US7326734B2 (en) * | 2003-04-01 | 2008-02-05 | The Regents Of The University Of California | Treatment of bladder and urinary tract cancers |
-
2006
- 2006-08-08 US US11/500,579 patent/US20070037193A1/en not_active Abandoned
- 2006-08-08 EP EP06291283A patent/EP1803809A3/en not_active Withdrawn
- 2006-08-09 TW TW095129257A patent/TW200741003A/zh unknown
- 2006-08-10 AR ARP060103503A patent/AR054909A1/es not_active Application Discontinuation
- 2006-08-10 JP JP2006218187A patent/JP2007061093A/ja active Pending
- 2006-08-10 SG SG200605449-8A patent/SG130141A1/en unknown
- 2006-08-10 IL IL177407A patent/IL177407A0/en unknown
- 2006-08-11 CA CA002553115A patent/CA2553115A1/en not_active Abandoned
- 2006-08-11 MX MXPA06009161A patent/MXPA06009161A/es not_active Application Discontinuation
- 2006-08-11 NO NO20063652A patent/NO20063652L/no not_active Application Discontinuation
- 2006-08-11 AU AU2006203479A patent/AU2006203479A1/en not_active Abandoned
- 2006-08-11 CO CO06079383A patent/CO5780135A1/es not_active Application Discontinuation
- 2006-08-11 ZA ZA200606661A patent/ZA200606661B/xx unknown
- 2006-08-12 KR KR1020060076462A patent/KR20080014936A/ko not_active Application Discontinuation
- 2006-08-14 BR BRPI0603206-0A patent/BRPI0603206A/pt not_active Application Discontinuation
- 2006-08-14 CN CNA2006101098017A patent/CN1916167A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2553115A1 (en) | 2007-02-12 |
| AR054909A1 (es) | 2007-07-25 |
| BRPI0603206A (pt) | 2007-05-15 |
| NO20063652L (no) | 2007-02-13 |
| EP1803809A3 (en) | 2007-12-19 |
| JP2007061093A (ja) | 2007-03-15 |
| US20070037193A1 (en) | 2007-02-15 |
| MXPA06009161A (es) | 2007-03-21 |
| IL177407A0 (en) | 2006-12-31 |
| ZA200606661B (en) | 2008-05-28 |
| KR20080014936A (ko) | 2008-02-15 |
| TW200741003A (en) | 2007-11-01 |
| AU2006203479A1 (en) | 2007-03-01 |
| SG130141A1 (en) | 2007-03-20 |
| CN1916167A (zh) | 2007-02-21 |
| EP1803809A2 (en) | 2007-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5780135A1 (es) | Modulacion de los receptores activados por el proliferador de peroxisomas | |
| DE60327205D1 (de) | Therapeutische antiköper mit reduzierten nebenwirkungen | |
| CL2021002498A1 (es) | Compuestos y conjugados de estos | |
| PE20210132A1 (es) | Anticuerpos anti-cd3 y usos de estos | |
| ES2621874T3 (es) | Anticuerpos para MUC16 y métodos de uso de los mismos | |
| GT200500298A (es) | Formulaciones de anticuerpos | |
| PE20120427A1 (es) | Anticuerpos contra el receptor de cgrp humano | |
| NO20074238L (no) | Fiksert dosering av HER-antistoffer | |
| EA200401198A1 (ru) | АНТИТЕЛА ПРОТИВ αvβ6 | |
| PE20200294A1 (es) | Anticuerpos que se unen especificamente a pd-1 y metodos de uso | |
| CL2008003782A1 (es) | Anticuerpo bivalente bioespecifico que comprende la cadena ligera y pesada de un anticuerpo que se une a un primer antigeno donde el dominio ch3 se reemplaza por ch1, y la cadena ligera y pesada de un anticuerpo que se une a un segundo antigeno, en el que el dominio ch3 esta reemplazado por cl; metodo de preparacion; y composicion. | |
| PE20221007A1 (es) | Anticuerpos anti-receptor de transferrina con afinidad disenada | |
| CR10563A (es) | Anticuerpos monoclonales ant-il-6 y usos de los mismos | |
| DE602006006200D1 (de) | Antikörper gegen 25-hydroxyvitamin d | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20120532A1 (es) | ANTICUERPOS ANTI-ActRIIB | |
| AR082205A1 (es) | Conjugados de anticuerpos multifuncionales | |
| HN2011001210A (es) | Anticuerpos humanos de alta afinidad para el receptor il-4 humano | |
| PE20150222A1 (es) | Anticuerpos multiespecificos | |
| CY1116632T1 (el) | Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου | |
| PE20121361A1 (es) | Antagonistas de pcsk9 | |
| RU2013138469A (ru) | АНТИТЕЛА К ИНТЕРЛЕЙКИНУ-1α И СПОСОБЫ ПРИМЕНЕНИЯ | |
| UY31433A1 (es) | Nuevos anticuerpos especificos de los peptidos - amiloides y sus usos como agentes de diagnostico o drogas | |
| RS54111B1 (en) | ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |